CGT Commercialization: Tackling Barriers to Market Success
Cell and gene therapies are growing rapidly, with FDA approvals at record highs and investment surging 30% to $15.2 billion. These transformative treatments offer hope for incurable conditions but face unique manufacturing, logistics, and administration challenges that can limit patient access.
This report explores six cutting-edge CGT innovations—from the first solid tumor cell therapy to personalized cancer vaccines—highlighting barriers to patient reach. Through case studies and expert insights, it offers strategies to address access, supply chain, and regulatory hurdles critical for commercial success.
Explore:
- Analysis of breakthrough therapies and rare disease treatments
- Commercialization challenges and solutions for autologous vs. allogeneic therapies
- Strategic guidance for managing logistics, patient identification, and provider education
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.